Pay in 4 interest-free payments of $5.74 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Through promoting collagen synthesis, angiogenesis, and cell migration, BPC-157 supports structural healing in tissues damaged by Lyme-related inflammation
This article is provided for educational purposes
Table of Contents Introduction and Discovery Molecular Structure and Origin Interactive Molecular Structure Detailed Mechanism of Action Scientific Research Review Benefits by Category with Evidence Ratings Regulatory Status Community Experience and Anecdotal Reports Side Effects and Safety Profile Drug Interactions Comparison with TB-500 Conclusion References Disclaimer Introduction and Discovery The Zagreb Discovery The story of BPC-157 begins in the laboratories of the University of Zagreb School of Medicine in Croatia during the early 1990s
TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days
Review: 1 At first, I was doubtful, but the results were amazing
